Quantiferon-CMV Guided Virostatic Prophylaxis After Heart Transplantation

Cytomegalovirus (CMV) infection is the most prevalent viral infection in heart transplant recipients. Current strategies for the prevention of CMV infection after heart transplantation include either universal prophylaxis (ranging from 100 to 200 days) or preemptive therapy1,2. Since the international consensus on CMV prophylaxis and treatment2 lacks definite recommendations on optimal CMV infection prevention and the duration of prophylaxis, these are subject to significant intercenter variability.

Source: The Journal of Heart and Lung Transplantation - January 20, 2020 Category: Transplant Surgery Authors: Gregor Poglajen, Gregor Zemlji č, Sabina Frljak, Andraž Cerar, Vesna Andročec, Tamara Božič, Mojca Bitenc, Renata Okrajšek, Miran Šebeštjen, Bojan Vrtovec Tags: Research Correspondence - clinical Source Type: research